Although cardiac resynchronization therapy (CRT) is indicated in patients with moderate to severe heart failure with a wide QRS complex (> 120 ms), current guidelines exclude many heart failure patients with a narrow QRS. Detecting mechanical dyssynchrony on echocardiography has become a promising tool in selecting patients with a narrow QRS who may respond to CRT. Several small single-center studies identified patients with a narrow QRS (using echocardiography-based dyssynchrony criteria) who responded favorably to CRT; however, the results of two recent pilot studies remain elusive. The results of the RethinQ study do not provide necessary evidence for making clinical treatment decisions in this population. The lack of definitive evidence is the strongest rationale for conducting an adequately powered, long-term, end point-driven, randomized controlled trial to investigate whether CRT therapy can improve morbidity and mortality outcomes in heart failure patients with a narrow QRS. Such a trial, the EchoCRT trial, has recently been launched. 
Introduction
Over 500.000 new patients each year are affected by the diagnosis of heart failure in the United States making it one of the biggest challenges to the Health Care System around the globe. 1 Recently it has been shown in large clinical, randomized, controlled trials that cardiac resynchronization therapy (CRT) improves morbidity and mortality in patients with moderate-to-severe heart failure [New York Heart Association (NYHA) functional class III-IV], left ventricular ejection fraction (LVEF) 35% or less, QRS > 120 ms on optimal medical therapy.
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However, a significant amount of patients meeting current guidelines are "nonresponders" based on clinical outcomes or echocardiographic remodeling. 5 In contrast, the majority of heart failure patients has a narrow QRS complex (Figure 1 ), 6 and is hence currently excluded to receive cardiac resynchronization.
Definition of mechanical dyssynchrony
Traditionally, cardiac dyssynchrony has been defined by prolongation of ventricular conduction measured by QRS-duration. Most of the currently available data on treatment success of CRT is therefore based on the selection of patients with a wide QRS complex (> 120ms). QRS-duration reflects mainly interventricular dyssynchrony and displays the total ventricular electrical activation. Therefore a rapid RV-depolarisation may offset delays in left ventricular activation resulting in a normal QRS duration despite the presence of LVdyssynchrony. 7 Several studies have demonstrated a weak predictive value of baseline QRSduration on response to CRT.
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Hence, QRS-width clearly has its limitations as a single parameter for dyssynchrony; consequently, interventricular dyssynchrony might not be the ideal target of CRT.
Several myocardial diseases go along with changes in cardiac structure and function, which result in regions of early and late LV-contraction leading to intraventricular mechanical dyssynchrony. Indeed, the latter has been identified as the main factor associated with impaired left-ventricular contractile function. As such, most of the current techniques for the assessment of cardiac dyssynchrony focus on left ventricular (intraventricular) dyssynchrony. Despite these results, SPMWD has several limitations and is only recommended as a supplemental parameter.
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The largest body of evidence comes from echocardiographic studies using different applications of tissue doppler imaging (TDI)-based criteria. Using TDI to assess temporal delay between septal and lateral wall peak systolic velocity, Bax et al. demonstrated an opposing wall delay of >65ms to predict both clinical response to CRT as well as reverse remodelling. 11 Yu et al. calculated the standard deviation (SD) of time to peak systolic velocity in 12 LV segments (‚Yu-Index') and demonstrated a similar predictive value; this approach, however, is considerably more time consuming. 12 Interestingly, Bleeker et al. found that 70% of patients with QRS-duration of >150ms showed severe mechanical dyssynchrony compared with only 27% of patients with a normal QRS duration. When QRS-duration was taken as a continuous variable, however, there was no relationship between QRS-duration and the extent of intraventricular dyssynchrony, 13 which was further supported by a study by Yu et al. 14 Considering that 27% of patients despite a narrow QRS complex exhibit significant intraventricular dyssynchrony by TDI, it is intriguing to speculate that these patients would also respond beneficially to CRT. This has been investigated in two smaller studies including 33 and 51 patients with QRS < 120ms. There was a similar improvement in symptoms and LV reverse remodeling compared to patients with a wide QRS complex and comparable intraventricular dyssynchrony (see below). 15, 16 Radial contraction or radial myocardial thickening, which is the main vector contributing to LV performance, can only insufficiently be analyzed by TDI due to inherent technical limitations (angle dependence). 2-D strain (speckle tracking) allows the assessment of radial LV-mechanics on the basis of routine gray-scale echocardiographic images. A cutoff value of 130ms for the time difference in peak septal to posterior wall strain (in midventricular short-axis images) predicted a significant increase in LVEF with 89% sensitivity and 83% specificity. Interestingly a subset of patients not meeting the cut-off value of TDI (>65ms) but instead demonstrating significant radial dyssynchrony by speckle tracking had a favorable response to CRT. 17, 18 In a recent study of 176 patients the two methods were combined; it was shown that patients who fulfilled both criteria had a high incidence of improvement after CRT, whereas patients with neither longitudinal nor radial dyssynchrony responded poorly, irrespective of QRS width. 19 Delgado et al. recently compared the predictive value of different speckle-tracking parameters (radial, circumferential and longitudinal strain) and found radial strain to be the best predictor (sensitivity 83%, specificity 80%) for response to CRT using the same cut-off value of >130ms (Figure 2 ). 20 Just recently Lim et al. proposed a "longitudinal strain delay index" by speckle tracking, defined as the sum of the difference between peak and end-systolic strain across 16 segments. Instead of measuring dyssynchrony, this method quantifies the potential gain of contractility that can be expected. Furthermore, by analyzing all segments, myocardial scars are also taken into account. Application of the "longitudinal strain delay index" demonstrated a strong predictive value for the response to CRT. 21 Real-time 3D-Echocardiography is another new technique being used to quantify intraventricular dyssynchrony. It allows the comparison of synchrony between all segments using semiautomatic LV contour detection algorithms. A systolic dyssynchrony index (SDI) is derived from dispersion of time to minimum regional volume for all 16 segments. SDI increases with worsening LV-systolic function. Of note, 37% of patients with moderate to severe impairment in LV-function had significant dyssynchrony despite a normal QRSduration. 22 . Marsan et al. have shown a sensitivity of 88% and specificity of 85% to predict response to CRT using a SDI cut-off value of 6.4%. 23 . The main limitations of this technique lie in the currently low spatial and temporal resolution with frame rates between 20 and 30/s.
Besides echocardiography, which is primarily used in dyssynchrony analysis, several other imaging modalities have been applied. In particular, cardiac magnetic resonance imaging (CMR) has shown to provide highly quantitative and reproducible data. 24, 25 Further methods are SPECT and CT, which will not further be discussed in this review. 26, 27 In summary, quantification of dyssynchrony is rather complex and there is currently no gold standard for the definition of mechanical dyssynchrony 10 . As there are minor differences in regional function in normal hearts 28 , pathophysiologically relevant dyssynchrony should not be diagnosed unless a certain threshold is identified. While in patients with a wide QRS complex interventricular and intraventricular dyssynchrony is frequently overt, it is more subtle in the case of narrow QRS. It is of pivotal importance to define criteria for dyssynchrony that are simple, reproducible and applicable to all patients with dyssynchrony.
CRT in patients with a narrow QRS is effective in single center studies
Several small single center studies have addressed the efficacy of CRT in heart failure patients with a narrow-as compared to those with a wide QRS complex based on echocardiographic criteria of dyssynchrony (table 1) . In an early trial, 38 patients with a wide and 14 patients with a narrow QRS complex, all of whom had echocardiographic signs of inter-(interventricular delay >20 ms) and intraventricular asynchrony (posterolateral left ventricular wall activation delay > interval between QRS onset and beginning of transmitral filling), were compared. After 6 months of CRT, an improvement in NYHA functional class and 6-minute walk distance as well as in LVEF, LVESD, LVEDD, and mitral regurgitation was observed to a similar degree in both groups. 29 In another study of 102 heart failure patients with functional NYHA class III or IV, TDI (standard deviation of the time to peak systolic velocity in12 LV segments > 32.6 ms) was used to depict subjects with mechanical LV asynchrony amongst the 51 patients with a narrow QRS. 3 months after CRT implantation, a reduction in LV end-systolic volume was observed in both the narrow and wide QRS patient group; along with this, an improvement of NYHA functional class, maximal exercise capacity, 6-min walk distance, LVEF, and mitral regurgitation was detected. In contrast, withholding CRT for 4 weeks resulted in loss of echocardiographic benefits. In both groups, LV reverse remodeling was determined to a similar extent by the degree of baseline mechanical asynchrony. 16 In a similar study, 33 consecutive patients with narrow QRS complex were prospectively compared to 33 consecutive patients with wide QRS complex. Inclusion criteria were NYHA functional class III or IV, LVEF ≤ 35%, and signs of LV dyssynchrony on TDI (maximum delay between peak systolic velocities among the 4 walls within the left ventricle ≥ 65 ms). No significant relationship between baseline QRS duration and LV dyssynchrony was observed, and improvement in clinical symptoms (NYHA functional class, 6 minute walk distance, quality of life) or LV reverse remodeling (LV end-systolic volume reduction, increase in LVEF) after 6 months of CRT was similar in both groups.
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A meta-analysis of the three aforementioned trial confirmed an improvement by CRT in mean LVEF as well as in NYHA functional class in heart failure patients with narrow QRS complex. 30 These small pilot studies hence demonstrate that patients selected on the basis of echocardiography-based asynchrony criteria can benefit from CRT independent of QRS duration. Interpretation is limited, however, due to the lack of hard endpoints, small sample size, and short duration of follow-up in these studies.
Recent pilot multi-center studies assessing CRT in patients with a narrow QRS (table 2)
In a recently published small pilot study (Cardiac Resynchronization Therapy in Patients with Heart Failure and Narrow QRS, RethinQ), 172 heart failure patients (126 with a narrow QRS (≤ 130msec) and 46 with a wide QRS complex (control group)) with a standard indication for an implantable cardioverter-defibrillator (ischemic or nonischemic cardiomyopathy and an ejection fraction ≤ 35%, NHYA functional class III), and evidence of mechanical dyssynchrony as measured on echocardiography were randomly assigned to CRT or to control (CRT off) for 6 months. 31 The study failed to reach its primary end point defined as an increase in peak oxygen consumption during cardiopulmonary exercise testing (46% vs. 41%, respectively), while peak oxygen consumption increased in a pre-specified subgroup of patients with a QRS interval of 120 msec or more receiving CRT therapy. While an analysis of secondary endpoints in the RethinQ study is questionable due to the rejection of the primary hypothesis, the inconsistencies in the secondary endpoints showing no improvement in quality-of-life and 6-minute walking test, but a statistically significant improvement of NYHA class, reinforce the inadequate powering of the study to draw conclusions related to clinical endpoints. Furthermore, a 28% relative reduction in heart failure events (24 events in 14 subjects [16.1%] in the CRT group, 41 events in 19 subjects [22.3%] in the control group) did not reach statistical significance, as there was no significant difference in mortality.
Several other weaknesses are equally inherent to this study. First, the selection criteria chosen to investigate intra-ventricular asynchrony are likely not the best approach to determine patients likely to benefit from CRT. Based on recent data from other trials, well established parameters with greater accuracy to predict mechanical dyssynchrony, speckletracking radial strain TDI in particular, are more appropriate to select candidates likely to respond to CRT as compared to the obsolete measurement of mechanical delay in septal-toposterior wall employed in RethinQ. Second, it is of note that large-scale and long-term clinical outcome trials, CARE-HF in particular, demonstrated that the clinical benefit of CRT becomes evident substantially later than after the six-month follow-up chosen in RethinQ, and increases over time, as it is expected from the beneficial impact of CRT on reverse left ventricular remodeling. Finally, and in contrast to previous and ongoing randomized clinical outcome trials with CRT, RethinQ was insufficiently powered to demonstrate clinical endpoints, and with only a six month follow-up period, too short to provide definite answers as to whether CRT reduces morbidity and mortality in heart failure subjects with narrow QRS.
Similar to Rethinq, the multi-center ESTEEM-CRT trial (presented at Heart Rhythm Society, 2008) evaluated the effects of CRT in HF patients with a narrow QRS and signs of mechanical dyssynchrony. Inclusion criteria were EF ≤ 35%, QRS < 120msec, NYHA functional class III, and mechanical dyssynchrony as defined as the standard deviation of time to peak velocity of 12 segments (Ts-SD) > 28.7ms. After 6 months of CRT, no improvement in peak oxygen consumption, LVEF, or LV end-systolic volume was observed; in contrast, subjective measures such as life score and NYHA functional class improved significantly.
Major limitations of ESTEEM-CRT included its non-randomized, single arm, unblinded design; hence, subjective measures such as functional class improvement are highly susceptible to placebo effect. Furthermore, the same general concerns as for Rethinq apply.
On the one hand, the employed TDI criteria may not have depicted patients suitable for CRT.
More importantly, however, the single arm design, low patient number, and the short followup period limit the validity of the study to assess the long-term effects of CRT on LV remodeling and, eventually, morbidity and mortality. Moreover, in contrast to single-center studies, interobserver variations in the assessment of dyssynchrony may be considerably higher across different centers in multi-center trials, which may have prevented uniform selection of appropriate patients.
The data from these two pilot multi-center trials hence provide a strong rational for an adequately powered, long-term, event-driven, randomized controlled trial to investigate morbidity and mortality in the large number of heart failure patients with narrow QRS.
Assessing asynchrony in patients with wide QRS -the PROSPECT trial
In the prospective, multi-center PROSPECT study (Predictors of Response to CRT), 498 heart failure patients from 53 centers were enrolled who fulfilled standard CRT indications (NYHA functional class III or IV, LVEF ≤ 35%, QRS ≥ 130msec). After 6 months of CRT, the clinical composite score was improved in 69% of 426 patients and the LV end-systolic volume (≥15% reduction) in 56% of 286 patients. However, both sensitivity and specificity of the twelve echocardiographic parameters used in the assessment of dyssynchrony varied widely for the prediction of clinical outcomes (6-74% and 35-91%, respectively) or left ventricular end-systolic volume response (9-77% and 31-93%, respectively). 32 In view of the modest sensitivity and specificity in this multicenter setting despite site training in acquisition methods and blinded core laboratory analysis, the authors concluded that no single echocardiographic measure of dyssynchrony may be recommended to improve patient selection for CRT beyond current guidelines. However, "response" to CRT is not solely dependent on the echocardiographic modality used to diagnose dyssynchrony, but also on several other factors. Indeed, presence of a myocardial scar as well as myocardial viability, 33, 34 position of LV lead placement, 35 etiology of heart failure as well as suboptimal pacemaker programming (with or without echocardiographic guidance) have all been shown to significantly affect the response to CRT.
Summary and Conclusion
Currently available practice guidelines of patient selection for CRT are unsatisfactory; on the one hand, a substantial number of patients selected according to guidelines do not respond to CRT, while other potential responders (especially certain patients with a narrow QRS) are currently excluded from this potentially life-saving therapy. Hence, novel algorithms for patient selection are required, and detection of mechanical dyssynchrony on echocardiography has emerged as a promising tool in this regard. However, objective echocardiographic quantification of dyssynchrony is complex, and determining which criteria are optimal to identify patients most likely to respond to CRT as well as adoption of universal definitions to reduce inter-and intraobserver variation will be of pivotal importance.
Furthermore, "response" to CRT is dependent on other factors such as lead positioning and optimal device programming, without which even the most optimal echocardiographic measure may become useless. While several small single center studies were able to identify patients with narrow QRS using echocardiography-based dyssynchrony criteria, who responded favorably to CRT, the results of two recent pilot studies remain elusive. Especially the initial experience from the RethinQ study does not provide the evidence necessary for making clinical treatment decisions in this population. This lack of definitive evidence is the strongest rationale for conducting an adequately powered, long-term, endpoint-driven, randomized controlled trial to investigate whether CRT therapy can improve morbidity and mortality outcomes in the large number of heart failure patients with narrow QRS.
Such a trial is now underway (Echocardiography Guided Cardiac Resynchronization
Therapy -EchoCRT; NCT00683696, www.clinicaltrials.gov). The EchoCRT trial evaluates the effects of CRT on morbidity and mortality in subjects with heart failure due to left ventricular systolic dysfunction with a narrow QRS width (<130 ms) and echocardiographic evidence of ventricular dyssynchrony. The primary efficacy objective of this trial is to demonstrate whether CRT (CRT=ON) will significantly reduce the combined endpoint of allcause mortality or first hospitalization for worsening heart failure (HF) -whichever comes first -in these subjects as compared to CRT=OFF therapy. 
